The Latest Breaking News from Novo Nordisk

Wegovy manufacturer says five-year study found drug reduced major cardiovascular events by 20% in overweight or obese people

Novo Nordisk stock surged Tuesday after the firm said its weight-loss drug reduced the risk of cardiovascular events.

Stomach paralysis risk raises concerns over popular weight loss and diabetes drugs

Ozempic and Saxenda among drugs being reviewed after five reports of suspected adverse reactions in patients

The FDA has received reports of stomach paralysis among patients taking Ozempic and Wegovy

Since the time a human first used a tool to make life easier, increased weight has been inevitable.

Artificial intelligence stocks including chipmaker Marvell Technology (MRVL), Arista Networks (ANET) and Synopsys (SNPS), which has launched AI-based chip-design tools, lead this weekend's watch list of five stocks near buy points. In addition to MRVL, ANET and SNPS stock, weight-loss drug leader Novo Nordisk (NVO) and Heico (HEI), a military…

Do pharmaceutical companies have influence over your doctor's prescription pad? It's relatively easy to check—but you shouldn't have to, experts say.

Concerns of weight loss and Type 1 diabetes are fueling the rise of our choice for this week's option position in shares of Novo Nordisk.